

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



(Please scan this QR Code to view the Offer Document)



Hannah Joseph Hospital
(Institute of Neurosciences & Trauma)

Hannah Joseph Hospital Limited

(formerly Hannah Joseph Hospital Private Limited)

Our Company was incorporated as "Hannah Joseph Hospital Private Limited" at Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 24, 2011, issued by the Registrar of Companies ("ROC"), Tamil Nadu, Chennai, Andaman and Nicobar Islands. Subsequently, our Company was converted to a public limited company and the name of our Company changed to 'Hannah Joseph Hospital Limited' and a fresh certificate of incorporation dated July 29, 2022 was issued by the RoC, Chennai. The CIN of our Company is U74999TN2011PLC082860. For details in relation to changes in the registered office of our Company, see **"History and Corporate Structure"** on page no. 152 of the Red Herring Prospectus.

Registered Office: 134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020. **Corporate Office:** Hannah Joseph Hospital RS 115- 3B2, Madurai- Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu India, 625009. **Mob. No.:** 9524729594; **Contact Person:** Yuvaraj Saravanan, Company Secretary & Compliance Officer
E-mail id: cs@hannahjosephhospital.com; **Website:** https://hannahjosephhospital.com/; **CIN:** U74999TN2011PLC082860

PROMOTERS OF OUR COMPANY: Mosesjoseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar

THIS OFFER IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 ("SEBI ICDR REGULATIONS") (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME").

THE ISSUE

INITIAL PUBLIC ISSUE OF UP TO 60,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF HANNAH JOSEPH HOSPITAL LIMITED ("COMPANY" / "ISSUER") FOR CASH AT A PRICE OF ₹ [●]- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●]- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ [●] LAKHS ("ISSUE"), OF WHICH 300000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [●]- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●]- PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.e. NET ISSUE OF 57,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [●]- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●]- PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.11%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN ALL EDITION OF FINANCIAL EXPRESS (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF JANSATTA (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND MADURAI EDITION OF MAKAL KURAL, A REGIONAL NEWSPAPER (THE REGIONAL LANGUAGE OF MADURAI WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED ("BSE SME") FOR THE PURPOSE OF UPLOADING ON THEIR WEBSITE.

CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED JANUARY 14, 2026

This is with reference to the red herring prospectus (RHP) dated January 14, 2026 for the proposed Initial public offering (IPO) of Hannah Joseph Hospital Limited
Investors are hereby informed of the following revisions in the Issue Structure on page 253 of RHP.

Particulars of the Issue	Market Maker Reservation Portion	QIBs	Non- Institutional Investor	Individual Investor
Minimum Bid Size	3,00,000 Equity Shares in multiple of [●] Equity shares	Such number of Equity Shares in multiples of [●] Equity Shares that shall be more than 2 Lots, and the Bid amount exceeds ₹2,00,000	Such number of Equity Shares in multiples of [●] Equity Shares that shall be more than 2 Lots, and the Bid amount exceeds ₹2,00,000	Such number of Equity Shares in multiples of [●] Equity Shares such that the minimum bid size shall be 2 Lots and the Bid amount exceeds ₹2,00,000
Maximum Bid Size	3,00,000 Equity Shares in multiple of [●] Equity shares	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid does not exceed the size of the Net Issue (excluding the Anchor portion)	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid does not exceed the size of the Net Issue (excluding the QIB portion)	Such number of Equity Shares in multiples of [●] Equity Shares such that the minimum bid size shall be 2 Lots and the Bid amount exceeds ₹2,00,000

PRICE BAND: ₹ 67 TO ₹ 70 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH

THE FLOOR PRICE IS 6.7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

THE PRICE TO EARNING RATIO BASED ON RESTATED DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE IS 15.51 TIMES AND AT THE CAP PRICE IS 16.2 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 3000 EQUITY SHARES AND IN MULTIPLES OF 1500 EQUITY SHARES THEREAFTER.

BID / ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, JANUARY 21, 2026[^]

BID / ISSUE OPENS ON: THURSDAY, JANUARY 22, 2026

BID / ISSUE CLOSES ON TUESDAY, JANUARY 27, 2026*

[^] The Company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date.
^{*} The UPI mandate end time and date shall be at 5:00 p.m. on the Issue Closing Day i.e., January 27, 2026.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

Hannah Joseph Hospital Limited, is a multi-speciality healthcare provider, strategically located in Madurai, operating in a two acres campus, centrally air-conditioned hospital with central water heating system with a combined bed capacity of 150 beds. We were assessed and found to comply with NABH Accreditation Standards for Hospital 5th edition and has been awarded with a Certificate of Accreditation from National Accreditation Board for Hospitals and Healthcare Provider. Further, we have also received NABL 128 Certification from National Accreditation Board for Testing and Calibration Laboratories.

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON THE SME PLATFORM OF BSE LIMITED. FOR THE PURPOSE OF THE ISSUE, THE DESIGNATED STOCK EXCHANGE SHALL BE BSE.

ALLOCATION OF THE OFFER

QIB PORTION	NOT MORE THAN 50 % OF THE NET ISSUE
INDIVIDUAL INVESTOR PORTION	NOT LESS THAN 35% OF THE NET ISSUE
NON-INSTITUTIONAL PORTION	NOT LESS THAN 15% OF THE NET ISSUE
MARKET MAKER PORTION	NOT LESS THAN 5% OF THE NET ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

In accordance with the recommendation of the Independent directors of our Company, the above provided price band is justified based on the qualitative factors, quantitative factors and KPI disclosed in the chapter title **"Basis for Issue Price"** beginning on page 97 of the Red Herring Prospectus.

RISKS TO INVESTORS

For details refer to section titled **"Risk Factor"** beginning on page 38 of the Red Herring Prospectus.

1. **Risk to Investors:** Summary description of key risk factors based on materiality.

- We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
- We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
- There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
- Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS- 3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
- While generating the UDIN for the Re-audited financial statements for FY 2023-24, the 'Certificate' category was selected due to unavailability of a specific 'Re-audit' or 'Restatement' option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.

2. **Details of suitable ratios of the Company for the latest full financial year ended March 31, 2025:**

Company Name	Face Value (₹)	Peer comparison		P/E Ratio	RoNW (%)	NAV per Equity Share	Total Income (₹ In lakhs)
		Current Market Price (₹)	EPS (₹) Basic & Diluted				
Hannah Joseph Hospital Limited	10	[●]	4.32	[●] ^a	14.74%	26.30	7790.05
Peer Group							
Asarfi Hospital Limited	10	180.00*	5.58	32.26	13.48%	41.39	12813.47
Maitreya Medicare Limited	10	208.00*	2.80	74.29	7.10%	39.49	4485.30

Source – All the financial information for listed industry peers mentioned above is on a standalone basis sourced from the Annual Reports/Information of the aforesaid companies uploaded on the NSE and BSE website for the year ended March 31, 2025

*CMP is of January 06, 2026.

^a To be included post finalization of the Issue Price.

Notes:

- The financial information for our Company is based on the Restated Financial Information as at and for the financial year ended March 31, 2025.
- P/E Ratio has been computed based on the closing market price of equity shares on the BSE and NSE on January 06, 2026 divided by the Diluted EPS as on March 31, 2025.
- RoNW is computed as net profit after tax divided by the net worth. Net worth has been computed as sum of share capital and reserves and surplus less accumulated losses, deferred expenditure and miscellaneous expenditure not written off.
- NAV is computed as the closing net worth divided by number of equity shares at the end of the year/period.
- The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is 6.7 times the face value at the floor price and 7 times the face value at the cap price.
- The Price band and Issue Price of will be determined by the Company in consultation with the Book Running Lead Manager, and in accordance with applicable law, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and quantitative and qualitative factors as described above.

3. **Weighted average return on net worth for last 3 financial years**

Sr. No.	Financial Year/Period	Basic & Diluted EPS (in ₹)	Weights	EPS x Weight
1	Financial Year ended March 31, 2025	4.32	3	12.96
2	Financial Year ended March 31, 2024	2.47	2	4.94
3	Financial Year ended March 31, 2023	0.63	1	0.63
Weighted Average			3.09	
Total			6	18.53
Period ended September 30, 2025*		3.07		

^{*}Not Annualized

Notes:

- The figures disclosed above are based on the Restated Financial Statements of the Company.
- The face value of each Equity Share is ₹ 10.00.
- Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year / Total of weights.
- Earnings per Share has been calculated in accordance with Indian Accounting Standard 33 – "Earnings per Share".

4. **Weighted average cost of acquisition**

a) **Price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on primary / new issuances of Equity Shares or convertible securities (excluding Equity Shares issued under the employee stock option schemes and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding ESOPs granted but not vested) in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Issuances")**

There are no issuance of Equity Shares or convertible securities, excluding shares issued under ESOP/ESOS and issuance of bonus shares, during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of 30 days.

b) **Price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on secondary sale or acquisition of equity shares or convertible securities (excluding gifts) involving our Promoters, the members of the Promoter Group during the 18 months preceding the date of filing of the Red Herring Prospectus, where the acquisition or sale is equal to or more than 5% of the paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").**

There have been no secondary sale/ acquisitions of Equity Shares or any convertible securities (excluding gifts), where our Promoters, or Promoter Group are a party to the transaction (excluding gifts) during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c) **Price per share based on the last five primary or secondary transactions**

Since there are no transactions to report under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoters / Promoter Group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction) not older than 3 years prior to the date of this Draft Red Herring Prospectus irrespective of the size of transactions is required to disclosed. Details of the same is provided below:

Primary Transaction:

Sr. No.	Date of Allotment	Nature of Specified Security	No. of specified security allotted	Face Value per share (in ₹)	Issue Price Per share (in ₹)	Nature of allotment	Nature of Consideration	Total Consideration (₹ in Lakhs)
1.	May 6, 2023	Equity Shares	32,250	10	200	Private Placement	Cash	64.50
2.	August 8, 2023	Equity Shares	50,000	10	200	Private Placement	Cash	100.00
3.	October 10, 2023	Equity Shares	25,000	10	200	Private Placement	Cash	50.00
4.	February 19, 2024	Equity Shares	1,89,268	10	205	Private Placement	Cash	388.00
5.	February 26, 2024	Equity Shares	52,195	10	205	Private Placement	Cash	166.98
Total			3,48,713					769.48
Weighted Average Cost of Acquisition (WACA) per Equity Share								220.66

Secondary Transaction:

Sr. No.	Date of Transfer	Name of Transferee	Name of Transferor	Number of Equity Shares Transferred	Face Value Per share (in ₹)	Transfer Price Per share (in ₹)	Total Consideration (₹ in Lakhs)
1.	August 08, 2024	Swetha Shree	Mosesjoseph Arunkumar	74,500	10	120	89.40
2.	August 19, 2024	Shanmugasundaram Selvakumar	Mosesjoseph Arunkumar	1,00,000	10	120	120.00
3.	August 19, 2024	Murthavanam. K	Mosesjoseph Arunkumar	1,28,500	10	120	154.20
4.	December 26, 2024	James Prabhukumar Moses	Maruthavanan K.	7,715	10	10	0.77
Total				3,10,715			364.37
Weighted Average Cost of Acquisition (WACA) per Equity Share							117.27

d) **Weighted average cost of acquisition, floor price and cap price:**

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor Price (i.e. ₹ [●])	Cap Price (i.e. ₹ [●])
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity/ convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of the Red Herring Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.**	N.A.	N.A.	N.A.
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares (equity/ convertible securities), where promoter promoter group entities or Selling Shareholders or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Red Herring Prospectus, where either acquisition or sale is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.**	N.A.	N.A.	N.A.
If there were no primary or secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Red Herring Prospectus, where either issuance or acquisition/ sale is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), the information has been disclosed for price per share of our Company based on the last five secondary transactions where promoter /promoter group entities or Selling Shareholders or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, during the last three years preceding to the date of filing of the Red Herring Prospectus irrespective of the size of the transaction.			
- Primary Transaction	220.66	[●]	[●]
- Secondary Transaction	117.27	[●]	[●]

****There were no primary / acquisition or secondary sale of shares (equity/ convertible securities) transactions in last 18 months from the date of the Red Herring Prospectus which are equal to or more than 5% of the fully diluted paid-up share capital of our Company.**

Continued on next page...

...continued from previous page.

ADDITIONAL INFORMATION FOR INVESTORS

1. Details of proposed/undertaken pre-issue placement from the DRHP filing date:
Our Company has not undertaken any PRE-IPO Placement from the DRHP filing date.
2. Transaction of shares aggregating up to 1% or more of the paid up equity share capital of the Company by promoter(s) and promoter group(s) from DRHP filing date:
Not Applicable
3. The aggregate pre-issue shareholding and post offer shareholding of Promoter/Promoter Group and additional Top 10 shareholders of the Company

Sr No	Pre-Issue shareholding			Post-Issue shareholding as at Allotment ⁽¹⁾			
	Shareholder	No. of Equity Shares ⁽¹⁾	Shareholding (in %) ⁽¹⁾	At the lower end of the price band (₹ 67)		At the upper end of the price band (₹ 70)	
				No. of Equity Shares ⁽¹⁾	Shareholding (in %) ⁽¹⁾	No. of Equity Shares ⁽¹⁾	Shareholding (in %) ⁽¹⁾
Promoter & Promoter Group							
1.	Mosesjoseph Arunkumar	1,51,62,925	90.80	1,51,62,925	66.80	1,51,62,925	66.80
2.	Fenn Kavitha Fenn Arunkumar	4,32,000	2.59	4,32,000	1.90	4,32,000	1.90
3.	James Prabhukumar Moses	29,430	0.18	29,430	0.13	29,430	0.13
4.	Arunkumar Nalina	15	0.00*	15	0.00*	15	0.00*
5.	Noyel Arunkumar	15	0.00*	15	0.00*	15	0.00*
6.	Daniel Dayanand Fenn	15	0.00*	15	0.00*	15	0.00*
Top 10 shareholder other than Promoter & Promoter Group							
1.	Elamperuvaluthi Asokan	4,77,015	2.86	●	●	●	●
2.	Ronak Sudhir Patel	1,10,000	0.66	●	●	●	●
3.	Kannan S.	1,00,000	0.60	●	●	●	●
4.	Shilpa Ajitkumar Patel	90,000	0.54	●	●	●	●
5.	N Arunkumar	60,060	0.36	●	●	●	●
6.	Viji	54,000	0.32	●	●	●	●
7.	Rajamani Veerapandian	20,020	0.12	●	●	●	●
8.	Dilip C Patel	20,000	0.12	●	●	●	●
9.	Maruthavanan K.	17,933	0.11	●	●	●	●
10.	Senthil Nathan Kadayavelan	12,500	0.07	●	●	●	●

⁽¹⁾Negligible Holding
Note:
1. Includes all options that have been exercised until the date of RHP and any transfer of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until the date of RHP
2. Based on the Issue price of ₹● and subject to the finalization of the basis of allotment.



BASIS FOR ISSUE PRICE

The section titled “Basis for Issue Price” on page 97 of the Offer Document has been updated with the above price band. Please refer to the website of the BRLM i.e. www.capitalsquare.in for the “Basis for Issue Price” updated with the above price band.
(You may scan the QR Code for accessing the website of CapitalSquare Advisors Private Limited.)

INDICATIVE TIMELINE FOR THE OFFER

Our Company may in consultation with the BRLM, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations.	
Sequence of Activities	Listing within T+3 days (T is Offer Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Up to 5 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc.) – Up to 4 pm on T Day. Electronic Applications (Syndicate Non-Retail, Non-Institutional Applications) – Up to 3 pm on T Day. Physical Applications (Bank ASBA) – Up to 1 pm on T Day. Physical Applications (Syndicate Non-Retail, Non-Institutional Applications of QIBs and NIIIs) – Up to 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day.
Bid Modification	From Offer opening date up to 5 pm on T Day.
Validation of Bid details with depositories	From Offer opening date up to 5 pm on T Day.
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges - Sponsor Banks - NPCI and NPCI - PSPs/TPAPs ** - Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timeline.	On daily basis BRLM to submit to SEBI, sought as and when.
UPI Mandate acceptance time	T Day – 5 PM
Offer Closure	T Day- 4 PM for QIB and NII Categories T day – 5 pm for Individual Investors and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day
Third party check on Non- UPI applications	On daily basis and to be completed before 1 PM on T+1 day
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA UPI ASBA	UPI ASBA - Before 09:30 pm on T day All SCSBs for Direct ASBA - Before 07:30 pm on T Day Syndicate ASBA - Before 07:30 pm on T Day
Finalization of rejection and completion of basis	Before 6 pm on T+1 day
Approval of basis by Stock Exchange	Before 9 pm on T+1 day
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA - To all SCSBs For UPI ASBA - To Sponsor Bank	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer; Completion before 4 pm on T+2 day for unlocking
Corporate action execution for credit of shares	Intimation before 2 pm on T+2 day; Completion before 6 pm on T+2 day

Filing of listing application with stock exchange and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of the Company, BRLM and RTA – before 9 PM on T+2 day. In newspapers – on T+3 day but not later than T+4 day
Trading starts	T+3 day
^{**PSPs/TPAPs = Payment Service Providers/Third Party Application Providers.} Submission of Bids (other than Bids from Anchor Investors):	
Bid/Offer Period (except the Bid/ Offer Closing Date)	
Submission and Revision in Bids	Only between 10:00 am and 5:00 pm (Indian Standard Time (‘IST’))
Bid / Offer Closing Date* (i.e. Thursday, January 22, 2026)	
Submission of Electronic Applications (Online ASBA through 3-in-1 accounts) – For Individual Investors other than QIBs and Non-Institutional Investors	Only between 10:00 am and up to 4:00 pm IST
Submission of Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA applications)	Only between 10:00 am and up to 4:00 pm IST
Submission of Electronic Applications (Syndicate Non-Individual Applications)	Only between 10:00 am and up to 3:00 pm IST
Submission of Physical Application (Bank ASBA)	Only between 10:00 am and up to 1:00 pm IST
Submission of Physical Application (Applications of QIBs and Non Institutional Investors)	Only between 10:00 am and up to 12:00 pm IST
Modification / Revision / cancellation of Bids	
Upward Revision of Bids by Individual Investors, QIBs and Non-Institutional Investors categories [†]	Only between 10:00 a.m. on the Bid/Offer Opening Date and up to 4:00 p.m. IST on Bid/Offer Closing Date
[†] UPI mandate end time and date shall be at 5:00 pm on the Bid/Offer Closing Date [†] Individual Investors, QIBs and Non-Institutional Investors can neither revise their bids downwards nor cancel/ withdraw their Bids. On the Bid/Offer Closing Date, the Bids shall be uploaded until: 4:00 p.m. IST in case of Bids by Individual Investors, QIBs and Non-Institutional Investors.	
Events	Indicative Dates
Bid/Issue Opening Date	Thursday, January 22, 2026
Bid/Issue Closing Date	Tuesday, January 27, 2026
Finalization of Basis of Allotment with the Designated Stock Exchange	On or about Wednesday, January 28, 2026
Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account	On or about Thursday, January 29, 2026
Credit of Equity Shares to Demat accounts of Allottees	On or about Thursday, January 29, 2026
Commencement of trading of the Equity Shares on the Stock Exchange	On or about Friday, January 30, 2026

ASBA*

Simple, Safe, Smart way of Application-
Make use of it!!!

*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details check section on ASBA.

Mandatory in Public Issues.
No cheque will be accepted.



UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to ₹500,000, applying through Registered Brokers, Syndicate, DPs & RTAs. UPI Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and the subsequent press releases, including press release dated June 25, 2021 read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by (i) Individual Investors in the Retail Portion. (ii) Non-Institutional Investors with an application size of up to ₹5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section “**Issue Procedure**” on page 256 of the Red Herring Prospectus. The process is also available on the website of Association of Investment Bankers of India (“**AIBI**”) and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. Kotak Mahindra Bank Limited has been appointed as the Sponsor Bank for the Issue, in accordance with the requirements of SEBI circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLM on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail Id: ipo.upi@npci.org.in. For Issue related grievance investors may contact: CapitalSquare Advisors Private Limited - Viveka Singhal / Pratima Keshari (022 6684 9999/ 022 6684 9946) (Email: mb@capitalsquare.in).

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (“**SCRR**”) read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50 % of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers (“**QIBs**”) (the “**QIB Portion**”), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“**Anchor Investor Portion**”), out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective bank accounts (including UPI ID for UPI Bidder using the UPI Mechanism) (defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“**SCSBs**”) or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see “**Issue Procedure**” beginning on page no. 256 of the Red Herring Prospectus.

Bidders/Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/ Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/ Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to the Issue. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants’ sole risk. Bidders/ Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database; otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAR and are in compliance with CBDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see section titled “**History and Corporate Structure**” on page 152 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section titled “**Material Contracts and Documents for Inspection**” on page 311 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on date of the RHP the Authorized share Capital of the Company is ₹2,500.00 Lakhs divided into 2,50,00,000 (Two Crore Fifty Lakhs) equity shares of face value of ₹10/- each. The issued, subscribed and paid-up share capital of the Company before the Offer is

₹1,669.84/- lakhs divided into 1,66,98,363 Equity Shares of face value of ₹10/- each. For details of the Capital Structure, see section titled “**Capital Structure**” on the page 73 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company, Mosesjoseph Arunkumar with 195000 Equity Shares, Fenn Kavitha Fenn Arunkumar with 5000 Equity Shares, aggregating to 200000 Equity Shares of ₹10/- each. Details of the main objects of the Company as contained in the Memorandum of Association, see section titled “**History and Corporate Structure**” on page 152 of the Red Herring Prospectus. For details of the share capital and capital structure of the Company see section titled “**Capital Structure**” on page 73 of the Red Herring Prospectus.

LISTING: The Equity Shares Issued through the Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited (“**BSE SME**”). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time, our Company has received “in-principle” approval letter dated August 13, 2025 from BSE Limited (“**BSE**”) for using its name in the Issue document for listing of our shares on the SME Platform of BSE. For the purpose of this Issue, the Designated Stock Exchange will be the BSE Limited (“**BSE**”).

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”): Since the Offer is being made in terms of Chapter IX of the SEBI ICDR Regulations. The Red Herring Prospectus has been filed with SEBI. In terms of the SEBI ICDR Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 237 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SME PLATFORM OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the contents of the Offer Document of the price at which the equity shares are offered has been cleared, solicited or approved by BSE nor does it certify the correctness, accuracy or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the Disclaimer Clause of BSE on page 239 of the Red Herring Prospectus.

RISKS IN RELATION TO FIRST OFFER: This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹10 each. The Floor Price, Cap Price and Issue Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under “**Basis for Issue Price**” on page no. 97 of the Red Herring Prospectus should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“**SEBI**”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section “**Risk Factors**” on page no. 26 of the Red Herring Prospectus.

CREDIT RATING: This being the issue of Equity Shares, no credit rating is required.

DEBENTURE TRUSTEES: This being the issue of Equity Shares, the appointment of debenture trustees is not required.

IPO GRADING: Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 there is no requirement of appointing an IPO Grading agency.

BASIS FOR ISSUE PRICE: The Issue Price is determined by the Company in consultation with the BRLM. The financial data presented in section titled “**Basis for Issue Price**” on page no. 97 of the Red Herring Prospectus are based on Company’s Restated Financial Statements. Investors should also refer to the section titled “**Risk Factors**” and “**Restated Financial Statement**” on page no. 26 and 179 respectively of the Red Herring Prospectus.

ISSUER’S ABSOLUTE RESPONSIBILITY: The Company, having made all reasonable inquiries, accepts responsibility for and confirms that the Red Herring Prospectus contains all information with regard to the Company and the Issue, which is material in the context of the Issue, that the information contained in the Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes the Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER OF THE OFFER
 CapitalSquare Advisors Private Limited Address: 208, 2nd Floor, AARPEE Centre, MIDC Road No.11, CTS70, Andheri - East, Mumbai – 400093 (India) Contact No: 022 6684 9999/ 022 6684 9946; Email: mb@capitalsquare.in Website: www.capitalsquare.in; Contact Person: Viveka Singhal / Pratima Keshari SEBI Registration number: INM000012219; CIN: U65999MH2008PTC0187863	 Bigshare Services Private Limited Address: Office no S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai – 400093, Maharashtra, India Contact No: +91 – 22 – 6263 8200; Email: ipo@bigshareonline.com Website: www.bigshareonline.com; Contact Person: Mr. Vinayak Morbale SEBI Registration number: INR000001385; CIN: U99999MH1994PTC076534	 Hannah Joseph Hospital (Institute of Neurosciences & Trauma) Yuvraj Saravanan Hannah Joseph Hospital Limited 134, Lake View Road K. K. Nagar, Madurai, Tamil Nadu, India, 625020 Tel. No: +91- 9524729594 Website: https://hannahjosephhospital.com/ E-mail: cs@hannahjosephhospital.com

AVAILABILITY OF RED HERRING PROSPECTUS: Investors should note that Investment in Equity Shares involves a degree of risk and are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the Company at <https://hannahjosephhospital.com/>, the website of the BRLM to the Issue at www.capitalsquare.in and the website of BSE SME Platform at <https://www.bseindia.com> respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Hannah Joseph Hospital Limited, Mob. No.: 9524729594, Registered office of the BRLM: CapitalSquare Advisors Private Limited, Contact No: 022 6684 9999/ 022 6684 9946 and at the selected locations of the Self Certified Syndicate Banks; Registered Brokers, Designated RTA Locations and Designated CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of BSE SME Platform and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): The investors are required to fill the application form and submit the same to the relevant SCSBs at the specific locations or registered brokers at the broker centers or RTA or DP’s. The SCSB will block the amount in the account as per the authority contained in application form. On allotment, amount will be unlocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund. For more details on the ASBA process, please refer to the details given in application forms and Red Herring Prospectus and also please refer to the section titled “**Issue Procedure**” on page 256 of the Red Herring Prospectus.

BANKERS TO THE ISSUE/PUBLIC ISSUE BANK/ ESCROW COLLECTION BANK AND REFUND BANKER/ SPONSOR BANK 1: Kotak Mahindra Bank Limited. **SPONSER BANK-2:** State Bank of India Limited.

AVAILABILITY OF ABRIDGED PROSPECTUS: A copy of the Abridged Prospectus shall be available at the website of SEBI at www.bseindia.com, the website of Book Running Lead Manager at www.capitalsquare.in and the website of the Issuer Company <https://hannahjosephhospital.com/>.

Investor should read the Red Herring Prospectus carefully, including the section titled “**Risk Factors**” beginning on page 26 of the Red Herring Prospectus before making any investment decision. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

On behalf of Board of Directors
Hannah Joseph Hospital Limited
Sd/-
Mr. Mosesjoseph Arunkumar
Chairman and Managing Director

Place: Madurai, Tamil Nadu
Date: January 17, 2026

Disclaimer: Hannah Joseph Hospital Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Red Herring Prospectus dated January 14, 2026 has been filed with the Registrar of Companies (“**ROC**”), Chennai. The Red Herring Prospectus is available on the website of the Book Running Lead Manager at www.capitalsquare.in the website of the BSE i.e., www.bseindia.com, and website of our Company at: <https://hannahjosephhospital.com/>.

Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled “**Risk Factors**” beginning on page 26 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the “**Securities Act**”) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in ‘offshore transactions’ in reliance on Regulation ‘S’ under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.